Slimbiotics partners with SUPCS to launch in Israel

“We are excited to partner with SUPCS to introduce our plant probiotic solutions to the Israeli market,” said Helmut Essl, founder of Slimbiotics GmbH. “SUPCS’s knowledge of the local landscape and strong relationships will be key as we navigate this market.“

The announcement follows a strategic alliance with DSM i-Health for the North American and Chinese markets. The SlimBiotics formula will be marketed under the Culturelle and Estroven brands and targeted towards metabolic health.

History

Slimbiotics GmbH was established in 2019 by Austrian entrepreneurs Helmut Essl and Alexander Schütz with the aim of creating plant-based, scientifically-backed biotics for consumers seeking to maintain a healthy weight and overall metabolic health.

Prior to Slimbiotics, Essl founded and led HSO Health Care GmbH, a company offering the probiotic solution Astarte targeting women’s urogenital health. Astarte was later acquired by Chr. Hansen in 2020.

Slimbiotics has concentrated on research and development of its Kimere-derived weight management probiotics.

The strains in Kimere were isolated and characterized for their anti-inflammatory and gut barrier enhancing properties to increase microbial diversity and potentially help reduce weight-related risks from changing metabolic conditions.

The company’s plant-derived strain combination includes L. fermentum K7-Lb1, L. fermentum K8-Lb1, and L. fermentum K11-Lb3.

Scientific substantiation

Initial results from the first clinical study of the product were published last summer in Nutrients. Scientists from Kiel Center of Innovation and Technology and Johannes-Gutenberg University in Germany reported that three months of supplementation with the three-strain combination led to significant reductions in body fat mass, body weight, waist circumference, BMI, and other indicators of metabolic health, compared to placebo.

* Source: Nutrients
2023, 15(13), 3039; doi: 10.3390/nu15133039
“Effect of a Probiotic and a Synbiotic on Body Fat Mass, Body Weight and Traits of Metabolic Syndrome in Individuals with Abdominal Overweight: A Human, Double-Blind, Randomised, Controlled Clinical Study”
Authors: C. Laue et al.